NCT02965599View on ClinicalTrials.gov

Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

December 27, 2016

Primary Completion Date

November 14, 2017

Study Completion Date

November 14, 2017

Conditions
Arthritis, Rheumatoid
Interventions
DRUG

GSK3117391

GSK3117391 (Dose A) is a white, opaque, gelatin capsule.

DRUG

Placebo

Placebo is a white, opaque, gelatin capsule.

Trial Locations (5)

540327

GSK Investigational Site, Târgu Mureş

15-879

GSK Investigational Site, Bialystok

82-300

GSK Investigational Site, Elblag

21-040

GSK Investigational Site, Świdnik

04-305

GSK Investigational Site, Warsaw

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT02965599 - Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK3117391 in Subjects With Rheumatoid Arthritis | Biotech Hunter | Biotech Hunter